Kyowa Hakko, an international health ingredients manufacturer and world leader in the development, manufacturing, and marketing of pharmaceuticals, nutraceuticals and food products recently participated in the International Society of Sports Nutrition (ISSN) Conference. ISSN is the only non-profit academic society dedicated to promoting the science and application of evidence-based sports nutrition and supplementation. The ISSN is the world's leader in providing science-based sports nutrition and supplement information.
Dr. Shintaro Ichikawa, Director of Technical Affairs at Kyowa Hakko USA, led the development and product launch of IMMUSE™, Lactococcus lactis strain plasma (LC-Plasma), in Japan and recently presented the topic “Immunological approach to reduce URTI symptoms in high-intensity training: the function of paraprobiotics” during the ISSN Conference.
IMMUSE™, discovered by Kirin Holding Company Limited, a pioneer in fermentation technology and parent company to Kyowa Hakko Bio, acts uniquely by activating plasmacytoid dendritic cells (pDC). pDC, a key leader of the immune system, has been shown to activate pivotal cells such as NK, Killer-T, Helper-T, and B cells, providing more comprehensive immune support.
Dr. Ichikawa explains, “It is well known that prolonged high-intensity exercise decreases immune function and increases the risk of upper respiratory tract infections (URTI). It is a serious problem for athletes because not only are URTIs unpleasant, they will also reduce training efficiency.”
According to Dr. Shintaro, “There is emerging evidence that has shown oral intake of LC- Plasma activates pDC and provides immune support . This novel approach to enhance the immune system may improve the experience of continuous high-intensity training.”
Validated by eleven human clinical studies consisting of nine efficacy studies and two safety studies, IMMUSE™ is a science-based ingredient that functions to get the immune system ready, supporting year-round health when taken regularly.* A series of safety data including in vitro, in vivo and in human have been collected. Deemed stable in a wide variety of applications including tablets, capsules and gummy formulations, IMMUSE™ is an innovative dietary supplement ingredient delivering a breakthrough approach for immune health.
Kyowa Hakko’s newest clinically-researched eye health ingredient, EYEMUSE™, debuted at ISSN. The first heat-treated paraprobiotic, Lacticaseibacillus paracasei KW3110, that has shown to promote healthy eye function.* Discovered by Kyowa Hakko’s parent-company Kirin Holding Company Limited, EYEMUSE™ stimulates the immune cells that produce regulatory cytokines such as IL-10 to support eye health.* By helping the regulatory cytokine induction and supporting a balanced immune response, EYEMUSE™ may help reduce digital stress related eye fatigue and other ocular discomforts.*
Kyowa Hakko USA is the North & South American office for Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development, manufacturing, and marketing of pharmaceuticals, nutraceuticals and food products. For more information visit Kyowa-USA.com.